Product Description
Eprazol is a potent proton pump inhibitor that works by interfering with the proton pump that secretes gastric acid on the cells lining the stomach, and its effect on inhibiting stomach acid is the strongest in its class
AI Product Description
*The following content is generated by AI and is for reference only.
Ilaprazole is a novel proton pump inhibitor (PPI) developed primarily for the treatment of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Chemically classified as a substituted benzimidazole derivative, it functions by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cells. This mechanism effectively suppresses both basal and stimulated gastric acid secretion, providing potent and prolonged relief from symptoms associated with excess stomach acidity. Unlike some older PPIs, Ilaprazole features a unique chemical structure that allows for rapid onset of action and sustained efficacy with once-daily dosing, enhancing patient compliance.
The molecular formula of Ilaprazole is C20H21ClN4O3S, reflecting its complex composition which includes chlorine, nitrogen, oxygen, sulfur, and carbon atoms arranged to optimize bioavailability and metabolic stability. Its corresponding CAS registry number is 259876-48-3, serving as a unique identifier for this specific pharmaceutical compound in global databases. The drug was notably approved in South Korea and has gained attention in other Asian markets for its improved pharmacokinetic profile compared to traditional agents like omeprazole or lansoprazole. Clinical studies suggest that Ilaprazole offers superior intragastric pH control, particularly during the night, which is crucial for healing erosive esophagitis and preventing ulcer recurrence.
Furthermore, the drug exhibits a favorable safety profile with minimal drug-drug interactions, largely due to its metabolism pathway not relying heavily on the CYP2C19 isoform, which often causes variability in response among different genetic populations. It is typically administered orally in tablet form, dissolving quickly to release the active ingredient. As the prevalence of acid-related diseases continues to rise globally, Ilaprazole represents a significant advancement in therapeutic options, offering clinicians a reliable tool for managing chronic gastric conditions. Its development underscores the ongoing evolution of gastroenterology treatments toward more targeted, efficient, and patient-friendly solutions for acid suppression therapy worldwide.
(All Rights Reserved)
